Cullinan Therapeutics

CGEMNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.090 B

$17.73 -1.23%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$219.9M

Loss-making

Shares outstanding

64,354,694

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#47MeiraGTxMGTX$1.21B
#48AlvotechALVO$1.19B
#49Cullinan TherapeuticsCGEM$1.09B
#50Odyssey TherapeuticsODTX$1.02B
#51Replimune GroupREPL$1.01B

Where these numbers come from

Share counts and financials for Cullinan Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.